554 related articles for article (PubMed ID: 28652105)
1. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Chrysant SG
J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
[TBL] [Abstract][Full Text] [Related]
2. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
4. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
Díez J
Eur J Heart Fail; 2017 Feb; 19(2):167-176. PubMed ID: 27766748
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/Valsartan (LCZ696) in Heart Failure.
Khder Y; Shi V; McMurray JJV; Lefkowitz MP
Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
[TBL] [Abstract][Full Text] [Related]
6. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Vardeny O; Miller R; Solomon SD
JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
[TBL] [Abstract][Full Text] [Related]
7. [Neprilysin inhibition and chronic kidney disease].
Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A
G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831
[TBL] [Abstract][Full Text] [Related]
8. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
9. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Lillyblad MP
Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
[TBL] [Abstract][Full Text] [Related]
11. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989
[TBL] [Abstract][Full Text] [Related]
12. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Marques da Silva P; Aguiar C
Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
Rodgers JE
Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
[TBL] [Abstract][Full Text] [Related]
16. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Ansara AJ; Kolanczyk DM; Koehler JM
J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
[TBL] [Abstract][Full Text] [Related]
17. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril/valsartan: beyond natriuretic peptides.
Singh JSS; Burrell LM; Cherif M; Squire IB; Clark AL; Lang CC
Heart; 2017 Oct; 103(20):1569-1577. PubMed ID: 28689178
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Burke RM; Lighthouse JK; Mickelsen DM; Small EM
Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]